1. Lyusov V. A., Taratukhin E. O. New insight on Atherothrombosis. Russ J Cardiol, 2011; 2 (II):5–15. Russian (Люсов В. А., Таратухин Е. О. Новый взгляд на атеротромбоз. Российский кардиологический журнал, 2011; 2 (II):5–15).
2. Gordeev I. G., Taratukhin E. O., Shaydyuk O. Yu. Clinical Physiology of Clotting. M.: Silicea-Polygraph, 2013, 128p. Russian (Гордеев И. Г., Таратухин Е. О., Шайдюк О. Ю. Клиническая физиология гемостаза. М.: Силицея-Полиграф, 2013, 128 с.)
3. Declerck P. J., Gils A. Three decades of research on Plasminogen Activator Inhibitor-1: a multifaceted serpin. Semin Theromb Hemost, 2013; Mar 16.
4. Malaguarnera M., Vacante M., Russo C., et al. Lipoprotein (a) in cardiovascular diseases. Biomed Res Int, 2013: 650989.
5. Gallagher S., Jain A. K., Archbold R. A. Intracoronary thrombolytic therapy: a treatment option for failed mechanical thrombectomy. Catheter Cardiovasc Interv, 2012; 80 (5):835–7.
6. Agarwal S. K. Pharmacoinvasive therapy for acute myocardial infarction. Catheter Cardiovasc Interv., 2011; 78 (1):72–5.
7. Parsons M., Spratt N., Bivard A. et al. A randomized trial of tenecteplase vs alteplase for acute ischemic stroke. New England J Med, 2012; 366:1099–107.
8. Tapson V. F. Thrombolytic therapy for acute pulmonaty embolism. Semin Thromb Hemost, 2013; Mar 28.
9. Marcos-Contreras O. A., Ganguly K., Yamamoto A. et al. Clot penetration and retention by plasminogen activators promote fibrinolysis. Biochem Pharmacol, 2014; 85 (2):216–22.
10. Armstrong P. W., Gershlick A. H., Goldstein P. et al. Fibrinolysis or primary PCI in ST-segment myocardial infarction. N Engl J Med, 2013; Mar 10.
11. Steering Comittee. Single-bolus tenecteplase plus heparin compared with heparin alone for normotensive patients with acute pulmonary embolism who have evidence of right ventricular dysfunction and myocardial injury: rationale and design of the Pulmonary Embolism Thrombolysis (PEITHO) trial. Am Heart J, 2012; 163 (1):33–8.
12. Huber K. Optimizing reperfusion therapy in acute ST-elevation myocardial infarction by a pharmaco-invasive treatment approach in a well-organized network. Eur Heart J, 2012; 33 (10):1184–6.
13. Larson D. M., Duval S., Sharkey S. W. et al. Safety and efficacy of a pharmacoinvasive reperfusion strategy in rural ST-elevation myocardial infarction patients with expected delays due to long-distance transfers. Eur Heart J, 2012; 33 (10):1232–40.
14. Crowder J. S., Hubble M. W., Gandhi S. et al. Prehospital administration of tenecteplase for ST-segment elevation myocardial infarction in a rural emergency medical services. Prehosp Emerg Care, 2011; 15 (4):499–505.
15. Welsh R. C., Westerhout C. M., Buller C. E. et al. Anticoagulation after subcutaneous enoxaparin is time sensitive in STEMI patients treated with tenecteplase. J Thromb Haemost, 2012; 34 (1):126–31.
16. Iyengar S. S., Nair T., Hiremath J. S. et al. Efficacy and safety of tenecteplase in 6000 patients with ST-elevation myocardial infarction from the Elaxim Indian registry. Indian Heart J, 2011; 63 (1):104–7.
17. Perrott J., Henneberry R. J., Zed P. J. Thrombolysis for cardiac arrest: case report and systematic review of controlled trials. Ann Pharmacother, 2010; 44 (12):2007–13.
